Health EducationTAOPENCT03647254
Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study)
A study testing Patient education group in people with Health Education and Patient Education as Topic, run by Francisco Javier Navarro Moya at 1 site in Spain.
Trial summary
Background: Oral anticoagulant drugs represent an essential tool in thrombo-embolic events prevention. Most used are vitamin K antagonists (VKA), which plasma level is monitored measuring prothrombin time using the International Normalized Ratio. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Health Education, Patient Education as Topic, Blood Coagulation Tests
- What is being tested?
- Patient education group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteSpain
- Study dates
- 1 Sep 2018to 1 Sep 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients on VKA treatment for at least the last six months in primary care environment.
- Patients on inappropriate INR level control.
- Patients in whom we have access to, at least, 80% of their INR levels. controls in last six months of treatment with VKA, although they are enrolled in another primary care center.
- Patients who have given written informed consent to take part in the study
Who cannot join
- Patients suffering from cognitive impairment wich prevents understanding what was written in the information sheet and informed consent.
- Limited mobility patients, terminal patients, alcoholism or drug addiction, severe psychiatric illness or any other reason which makes patients to be present at center´s meetings imposible.
Trial locations and contacts
1 site in 1 country.
Francisco J Navarro Moya, Enfermera contact
Spain1 site, 1 recruiting
- Recruiting
Distrito Sanitario Málaga. Servicio Andaluz de Salud
Málaga, 29009
Francisco Javier Navarro-Moya, Nurse, +34951031325, fjavier.navarro.sspa@juntadeandalucia.es
Doctor
About this study
Official title: Effectivity of a Joint Didactic Intervention by School for Patients on Inappropriate Control Prothrombin Time Anticoagulated Patients. Protocol for Developing a Randomized and Controlled Clinical Trial
Background: Oral anticoagulant drugs represent an essential tool in thrombo-embolic events prevention. Most used are vitamin K antagonists (VKA), which plasma level is monitored measuring prothrombin time using the International Normalized Ratio. If it takes values out of recommended range, the patient will have a higher risk of suffering from thromboembolic or hemorrhagic complications. Previous researches have shown that, at best, only 33% of total patients keep values on therapeutic level.
The investigators intend to improve International Normalized Ratio control figures by a joint didactic intervention based on Junta de Andalucía School for Patients method that will be practiced by anticoagulated patients themselves.
Read more
Methods: A randomized clinical trial was carried out at primary care centers from one healthcare area in Malaga (Andalusia, Spain). Study population: patients included on oral anticoagulant therapy program using vitamin K antagonists.
First step: detection of patients on oral anticoagulation program with International Normalized Ratio on therapeutic level during 65% or less over total time. Second step: patients with inappropriate International Normalized Ratio control were practiced a joint didactic intervention "from peer to peer", by a previously trained and expert anticoagulated patient.
Study variables: time on therapeutic levels before and after intervention, sociodemographic variables, vital signs, existence of cardiovascular risk factors, basic blood test, other prescribed drugs, accompanying diseases and social support.
Almost-experimental analytic study with before-after statistical analysis of the intervention. Lineal regression models were applied on main variables results (International Normalized Ratio value, time on therapeutic level) inputting sociodemographic variables, accompanying diseases and social support.
Read the detailed description
Background and current status:
It has been proved that oral anticoagulant therapy (OAT) is effective in preventing situations with high risk of thromboembolic events and in treating them. It significantly decreases ischemic stroke rates as well as their severity and death risk. However it is a therapy with special features, highlighting: doses and response variability, the close therapeutic range, interactions with other drugs and foods, and potentially severe side effects. This fact compels the investigators to make a close monitoring of those patients.
An important impact in developing cardioembolic or hemorrhagic events due to a inappropriate coagulation control using vitamin K antagonists (VKA), has been described; because of control variations around 15% could result in so relevant clinical problems.
The main OAT indications are deep vein thrombosis, pulmonary embolism, embolic conditions prevention in patients suffering from atrial fibrillation or heart prosthetic valve wearers. Most common embolic event is ictus, which could lead to an important inability and dependence state, what would associate a significant increase in health resources use and costs. Atrial fibrillation (AF) is nowadays the pathology which requires most anticoagulant therapy indications. This fact is partially due to the population aging, since there are both incidence and prevalence increases of this arrhythmia, specially in elderly patients.
Control of patients on OAT were performed in hospitals until a few years ago; nevertheless, changes in social and healthy contexts besides the expansion in this drugs prescribing joined to primary health care qualification and evolution, the development of coagulation handheld measuring devices and the need to improve patients accessibility, had justified the control decentralization and due to this facts, OAT monitoring can be practiced to stable patients on primary care.
When the need of receiving anticoagulation has been stablished, this could be implemented basically using heparin or vitamin-K antagonists or coumadin or new direct action oral anticoagulants as dabigatran, rivaroxaban, apixaban or edoxaban.
The prothrombin time measuring standardization using international normalized ratio (INR) allows the investigators to obtain reliable results in different laboratories. The development of coagulation handheld measuring devices to match INR in capillary blood with high sensitivity and reliability, has made that possible patients on anticoagulant therapy can be controlled on primary care. This allow the investigators a comprehensive approach and control of these patients.
Educational and behavioural interventions could improve VKA anticoagulated patients ability to keep an INR appropriate control using their progresses in knowledge and understanding of the action mechanisms of anticoagulants drugs. A recent research included in Cochrane regarding to those interventions notes that education is particularly important to provide information about safety for patients suffering AF on OAT and let patients to take their own well founded decisions about treatment options and to manage their OAT. However, it could be inferred there are not enough evidences to stablish definite conclusions about educational health interventions impact in INR behaviour in patients suffering from AF on OAT.
In the investigators environment, patients who initiate treatment with VKA are trained at their hematology units until they get a suitable INR level control. After that, patients are followed and evaluated in primary care. The amount of patients with AF on anticoagulation with VKA is high, however, INR levels control results are not ideal.
Therefore, in these three research articles recently conducted in Spain with patients on VKA, it can be observed an inappropriate anticoagulation control.
On the other hand, it should be noted that these chronic patients use to suffer many other conditions and they usually take a lot of medication which makes improve of education aspects aimed at self care and effective health self-management which is absolutely necessary. Selfcare support programs are presented as a tool to accomplish a change in paternalistic method to other one in which citizens could receive more information about their health state (this fact is in accordance with people requests, demonstrated by a rise in the internet consulting about health issues).
"Expert patients" programs, in which instructors are patients with chronic conditions similar to those who receive the training and so they could play a role model, occupying a prominent place inside the selfcare educational initiatives set.
Through the present research the investigators try to show that an organised group educational intervention, conducted by using School for Patients method on VKA anticoagulated patients is able to improve inappropriate INR levels control.
METHODS:
The investigators performed a randomized clinical trial over a period of 12 months.
Study area: one healthcare area in Malaga (Spain) where 741.000 inhabitants from rural or urban population are cared for. It is organized in 33 primary care centers and 19 local doctor´s offices.
Study population: patients on OAT program receiving VKA presenting inappropriate INR levels control and belonging to four primary care centers. Setting the limits and justification of the sample size:
Total population from the health centers which take part in the study amount to approximately 50.000 inhabitants.
Step I: If it is taken into account that prevalence of patients on OAT is about 1.5% of general population, it can be claimed that target population to initiate the study will be 750 anticoagulated patients. It has been observed in previous researches that at least 33% of these patients would not have an appropriate INR level control. In order to reach an accuracy about 4% in the estimate proportion using a normal asymptotic confidence interval with a correction to finite populations on bilaterally 95% and assuming that expected population is about 33% and population total size is 750, it will be necessary to include 311 experimental units in this study.
Step II: If it is accepted an alfa risk of 0.05 and a beta risk of 0.20 in a bilateral contrast between study group and control group, 312 individual will be required (156 in each group) to detect differences equal or higher than 15% between both groups in primary target. It has been estimated a tracking loss rates of 10%. It will be assumed as losts those individual impossible to be located, or those who do not accept to take part or those who do not attend to scheduled revisions, in accordance to the study intervention plan, as well as deceases occurring within six months since the intervention. Given the relevant impact of the development of cardioembolic or hemorrhagic events due to inappropriate INR control, changes about 15% could have great clinical relevance.
Variables. Operative definition The main variable to assess in this study is time on INR therapeutic levels in the last six months receiving VKA treatment. Appropriate INR level control will be assessed in two ways: measuring the therapeutic INR values percentages or Time percentages in therapeutic values estimated using Rosendaal method. It supposes to record the figure of INR value and the date in which the test was carried out. The therapeutic INR values percentages are defined by their acceptable values according to the pathology the patient suffers. It used to be from 2 to 3 if it is about atrial fibrillation or from 2.5 to 3.5 if thromboembolism prevention is carried out after a heart valve surgery has been performed. So, this quantitative variable has to be measured to calculate patients percentage on appropriate range, according to the patient condition.
Independent variables also called study variables are those which could affect to result variable. The investigators are going to classify them in eight groups to make easier their analysis.
Sociodemographic: age and gender. Somatometry and vital signs: Body mass index (BMI), diastolic and systolic blood pressure, and heart rate.
Cardiovascular risk factors: smoking habit, diabetes, arterial hypertension, dyslipidemia and chronic renal failure.
Cardiovascular conditions: atrial fibrillation (AF), interventional cardiac valve diseases with or without AF, ischemic cardiopathy, thromboembolic diseases history (stroke, transient ischemic attack), hemorrhagic stroke, congestive heart failure.
Blood test: Glomerular filtration rates, total cholesterol, HDL and LDL cholesterol and triglycerides. They will be obtained from the last blood test carried out to the patient.
Use of accompanying medication: total number of drugs, anticoagulant type. Consumption of "gastric protector".
Dietary habits: usual consumption of food rich in vitamin K, alcohol consumption.
Data collecting: All variables detailed previously were collected as long as they were suitable in digital medical history or it could be directly obtained from the patient during the medical interview, without the need of changing health center usual clinical practice, over the 6 months prior to the intervention.
First step: patients on OAT program enrolled in several primary health centers belonging to a healthcare area of Málaga were evaluated at the study moment attending to their clinical characteristics. The measurements obtained from the digital clinical history in the last six months before the beginning of the study were recorded, as well as the rest of variables.
Second step: Once the study of the VKA anticoagulation control degree has been performed, patients on inappropriate control were selected. A list of patients with deficient INR control in participant health centers was made. It was considered an inappropriate INR control when the therapeutic INR values percentages was less than 65%, using Rosendaal method to obtain them. In case of no availability, INR control was considered inappropriate when therapeutic INR values percentage resulted less than 60%. In any of the assumptions, the assessment period was at least the last six months.
- Being tested
- Patient education group
- Keywords
- Anticoagulants, Warfarin
- Medical subject headings
- Health Education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient education groupBehavioural
Also called Control group
Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
| Study group | Role | What they receive |
|---|---|---|
| Patient Education Group | Experimental | A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls Receives: Behavioral: Patient education group |
| Control group | No intervention | Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time on INR therapeutic levels in the last six months receiving VKA treatment
Appropriate INR level control will be assessed in two ways: measuring the therapeutic INR values percentages or Time percentages in therapeutic values estimated using Rosendaal method
Measured: Six months
Secondary outcomes (25)
Sociodemographic
Record of age and sex.
Measured: Six months
Body mass index (BMI)
Determination of the body mass index calculated as the weight measured in kilograms (kg) divided by the height measured in meters squared (weight / height2) (Kg /m2).
Measured: 0 and 12 months.
Diastolic and systolic blood pressure
Determination of diastolic and systolic blood pressure measured in millimeters of mercury (mm / Hg), average of 2 determinations.
Measured: 0 and 12 months.
Heart rate
Determination of the number of heart beats per minute, average of 2 Determination of
Measured: 0 and 12 months.
Smoking habit
Incidence of smoker's habit status in the electronic medical record.
Measured: 0 and 12 months.
diabetes
Incidence of the condition of diabetes in the electronic medical record.
Measured: 0 and 12 months.
Arterial hypertension
Incidence of diagnosis of hypertension in the electronic medical record.
Measured: 0 and 12 months.
Dyslipidemia
Incidence of the diagnosis of dyslipidemia in the electronic medical record.
Measured: 0 and 12 months.
Chronic renal failure
Incidence of the diagnosis of chronic renal failure in the electronic medical record.
Measured: 0 and 12 months.
Atrial fibrillation
Incidence of diagnosis of atrial fibrillation in the electronic medical records of patients.
Measured: 0 and 12 months.
Interventional cardiac valve diseases with or without atrial fibrillation
Incidence of diagnosis of interventional cardiac valve diseases in the electronic medical records of patients.
Measured: 0 and 12 months.
Ischemic cardiopathy
Incidence of diagnosis of Ischemic cardiopathy in the electronic medical records of patients.
Measured: 0 and 12 months.
Thromboembolic diseases history (stroke, transient ischemic attack)
Incidence of diagnosis of thromboembolic diseases history (stroke, transient ischemic attack) in the electronic medical records of patients.
Measured: 0 and 12 months.
Hemorrhagic stroke
Incidence of diagnosis of hemorrhagic stroke in the electronic medical records of patients.
Measured: 0 and 12 months.
Congestive heart failure
Incidence of diagnosis of congestive heart failure in the electronic medical records of patients.
Measured: 0 and 12 months.
Glomerular filtration rates
Determination of total Glomerular filtration rates in mL/min/1,73 m2. Change of basal to 12 months.
Measured: 0 and 12 months.
Total cholesterol
Determination of total cholesterol measured in milligrams per deciliter (mg/dl). Change of basal to 12 months.
Measured: 0 and 12 months.
HDL Cholesterol
Determination of HDLc (high-density lipoprotein colesterol). LDLc measured in milligrams per deciliter (mg/dl)., (low-density lipoprotein colesterol). HDLc measured in milligrams per deciliter (mg/dl). Change of basal to 12 months.
Measured: 0 and 12 months.
LDL cholesterol
Determination of LDLc (low-density lipoprotein colesterol). LDLc measured in milligrams per deciliter (mg/dl). Change of basal to 12 months.
Measured: 0 and 12 months.
Triglycerides
Determination of total triglycerides measured in milligrams per deciliter (mg/dl). Change of basal to 12 months.
Measured: 0 and 12 months.
Total number of drugs
Determination of the total number of different medications prescribed in the electronic medical records of patients. Change of basal to 12 months
Measured: 0 and 12 months.
Anticoagulant type
Determination of the anticoagulant type prescribed in the electronic medical records of patients. Change at baseline and at 12 months.
Measured: 0 and 12 months.
Consumption of "gastric protector"
Determination of the Consumption of "gastric protector" prescribed in the electronic medical records of patients. Change at baseline and at 12 months.
Measured: 0 and 12 months.
Usual consumption of food rich in vitamin K
Change in usual consumption of food rich in vitamin K. Change at baseline and at 12 months
Measured: 0 and 12 months.
Alcohol consumption
Change in usual Alcohol consumption. Change at baseline and at 12 months
Measured: 0 and 12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2018
- Study start1 Sep 2018
- Primary completion31 Dec 2020 (estimated)
- Study completion1 Sep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (26)Papers the sponsor has linked to this study.
- Other trials for Health EducationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Francisco Javier Navarro Moya
- Sponsor type
- Other government
- Collaborators
- Andaluz Health Service
- Responsible party
- Sponsor-investigator, Francisco Javier Navarro Moya, Andaluz Health Service
- Investigators
- Francisco J Navarro Moya, Enfermera, Study chair, Servicio de salud pública de Andalucía. Málaga, España
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03647254
- Sponsor's protocol ID
- AndaluzHS
- Acronym
- TAOPE
- Status last verified
- Sep 2018
- First submitted
- 8 Aug 2018
- Last updated
- 27 Sep 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292.
PubMed 22315269Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006;117(5):493-9. doi: 10.1016/j.thromres.2004.11.025. Epub 2004 Dec 25.
PubMed 16517250Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67. doi: 10.7326/0003-4819-146-12-200706190-00007.
PubMed 17577005Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008 Nov;1(2):84-91. doi: 10.1161/CIRCOUTCOMES.108.796185. Epub 2008 Nov 5.
PubMed 20031794Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. Epub 2012 May 3. No abstract available.
PubMed 22555213Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011 Oct;13(10):1375-85. doi: 10.1093/europace/eur194. Epub 2011 Jul 14.
PubMed 21757483Gomez-Doblas JJ, Muniz J, Martin JJ, Rodriguez-Roca G, Lobos JM, Awamleh P, Permanyer-Miralda G, Chorro FJ, Anguita M, Roig E; OFRECE study collaborators. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol (Engl Ed). 2014 Apr;67(4):259-69. doi: 10.1016/j.rec.2013.07.014. Epub 2013 Nov 25.
PubMed 24774588Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009 Dec 1;104(11):1534-9. doi: 10.1016/j.amjcard.2009.07.022.
PubMed 19932788Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165-77. doi: 10.2147/cia.s4308. Epub 2009 May 14.
PubMed 19503778Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.
PubMed 19762550Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124.
PubMed 21282258European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. No abstract available.
PubMed 20802247Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ. 2014 Apr 14;348:g2116. doi: 10.1136/bmj.g2116.
PubMed 24733535Riley RS, Rowe D, Fisher LM. Clinical utilization of the international normalized ratio (INR). J Clin Lab Anal. 2000;14(3):101-14. doi: 10.1002/(sici)1098-2825(2000)14:33.0.co;2-a.
PubMed 10797608Cardenas Valladolid J, Mena Mateo J, Canada Dorado MM, Rodriguez Morales D, Sanchez Perruca L. [Implementation and improvement in a care program for the elderly on multiple medications in a primary care area]. Rev Calid Asist. 2009 Feb;24(1):24-31. doi: 10.1016/S1134-282X(09)70072-7. Epub 2009 Feb 23. Spanish.
PubMed 19369139
Study at a glance
From the registry record, last updated by the sponsor on 27 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectivity of a Joint Didactic Intervention by School for Patients on Inappropriate Control Prothrombin Time Anticoagulated Patients. Protocol for Developing a Randomized and Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT03647254
- Acronym / sponsor ID
- TAOPE / AndaluzHS
- Keywords
- Anticoagulants, Warfarin
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1 participants (estimated)
- Lead sponsor
- Francisco Javier Navarro MoyaOther government
- Collaborators
- Andaluz Health Service
- Study start
- 1 Sep 2018 (actual)
- Primary completion
- 31 Dec 2020 (estimated)
- Study completion
- 1 Sep 2021 (estimated)
- First posted
- 27 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Oral anticoagulant drugs represent an essential tool in thrombo-embolic events prevention. Most used are vitamin K antagonists (VKA), which plasma level is monitored measuring prothrombin time using the International Normalized Ratio. If it takes values out of recommended range, the patient will have a higher risk of suffering from thromboembolic or hemorrhagic complications. Previous researches have shown that, at best, only 33% of total patients keep values on therapeutic level.
The investigators intend to improve International Normalized Ratio control figures by a joint didactic intervention based on Junta de Andalucía School for Patients method that will be practiced by anticoagulated patients themselves.
Methods: A randomized clinical trial was carried out at primary care centers from one healthcare area in Malaga (Andalusia, Spain). Study population: patients included on oral anticoagulant therapy program using vitamin K antagonists.
First step: detection of patients on oral anticoagulation program with International Normalized Ratio on therapeutic level during 65% or less over total time. Second step: patients with inappropriate International Normalized Ratio control were practiced a joint didactic intervention "from peer to peer", by a previously trained and expert anticoagulated patient.
Study variables: time on therapeutic levels before and after intervention, sociodemographic variables, vital signs, existence of cardiovascular risk factors, basic blood test, other prescribed drugs, accompanying diseases and social support.
Almost-experimental analytic study with before-after statistical analysis of the intervention. Lineal regression models were applied on main variables results (International Normalized Ratio value, time on therapeutic level) inputting sociodemographic variables, accompanying diseases and social support.
Detailed description
Background and current status:
It has been proved that oral anticoagulant therapy (OAT) is effective in preventing situations with high risk of thromboembolic events and in treating them. It significantly decreases ischemic stroke rates as well as their severity and death risk. However it is a therapy with special features, highlighting: doses and response variability, the close therapeutic range, interactions with other drugs and foods, and potentially severe side effects. This fact compels the investigators to make a close monitoring of those patients.
An important impact in developing cardioembolic or hemorrhagic events due to a inappropriate coagulation control using vitamin K antagonists (VKA), has been described; because of control variations around 15% could result in so relevant clinical problems.
The main OAT indications are deep vein thrombosis, pulmonary embolism, embolic conditions prevention in patients suffering from atrial fibrillation or heart prosthetic valve wearers. Most common embolic event is ictus, which could lead to an important inability and dependence state, what would associate a significant increase in health resources use and costs. Atrial fibrillation (AF) is nowadays the pathology which requires most anticoagulant therapy indications. This fact is partially due to the population aging, since there are both incidence and prevalence increases of this arrhythmia, specially in elderly patients.
Control of patients on OAT were performed in hospitals until a few years ago; nevertheless, changes in social and healthy contexts besides the expansion in this drugs prescribing joined to primary health care qualification and evolution, the development of coagulation handheld measuring devices and the need to improve patients accessibility, had justified the control decentralization and due to this facts, OAT monitoring can be practiced to stable patients on primary care.
When the need of receiving anticoagulation has been stablished, this could be implemented basically using heparin or vitamin-K antagonists or coumadin or new direct action oral anticoagulants as dabigatran, rivaroxaban, apixaban or edoxaban.
The prothrombin time measuring standardization using international normalized ratio (INR) allows the investigators to obtain reliable results in different laboratories. The development of coagulation handheld measuring devices to match INR in capillary blood with high sensitivity and reliability, has made that possible patients on anticoagulant therapy can be controlled on primary care. This allow the investigators a comprehensive approach and control of these patients.
Educational and behavioural interventions could improve VKA anticoagulated patients ability to keep an INR appropriate control using their progresses in knowledge and understanding of the action mechanisms of anticoagulants drugs. A recent research included in Cochrane regarding to those interventions notes that education is particularly important to provide information about safety for patients suffering AF on OAT and let patients to take their own well founded decisions about treatment options and to manage their OAT. However, it could be inferred there are not enough evidences to stablish definite conclusions about educational health interventions impact in INR behaviour in patients suffering from AF on OAT.
In the investigators environment, patients who initiate treatment with VKA are trained at their hematology units until they get a suitable INR level control. After that, patients are followed and evaluated in primary care. The amount of patients with AF on anticoagulation with VKA is high, however, INR levels control results are not ideal.
Therefore, in these three research articles recently conducted in Spain with patients on VKA, it can be observed an inappropriate anticoagulation control.
On the other hand, it should be noted that these chronic patients use to suffer many other conditions and they usually take a lot of medication which makes improve of education aspects aimed at self care and effective health self-management which is absolutely necessary. Selfcare support programs are presented as a tool to accomplish a change in paternalistic method to other one in which citizens could receive more information about their health state (this fact is in accordance with people requests, demonstrated by a rise in the internet consulting about health issues).
"Expert patients" programs, in which instructors are patients with chronic conditions similar to those who receive the training and so they could play a role model, occupying a prominent place inside the selfcare educational initiatives set.
Through the present research the investigators try to show that an organised group educational intervention, conducted by using School for Patients method on VKA anticoagulated patients is able to improve inappropriate INR levels control.
METHODS:
The investigators performed a randomized clinical trial over a period of 12 months.
Study area: one healthcare area in Malaga (Spain) where 741.000 inhabitants from rural or urban population are cared for. It is organized in 33 primary care centers and 19 local doctor´s offices.
Study population: patients on OAT program receiving VKA presenting inappropriate INR levels control and belonging to four primary care centers. Setting the limits and justification of the sample size:
Total population from the health centers which take part in the study amount to approximately 50.000 inhabitants.
Step I: If it is taken into account that prevalence of patients on OAT is about 1.5% of general population, it can be claimed that target population to initiate the study will be 750 anticoagulated patients. It has been observed in previous researches that at least 33% of these patients would not have an appropriate INR level control. In order to reach an accuracy about 4% in the estimate proportion using a normal asymptotic confidence interval with a correction to finite populations on bilaterally 95% and assuming that expected population is about 33% and population total size is 750, it will be necessary to include 311 experimental units in this study.
Step II: If it is accepted an alfa risk of 0.05 and a beta risk of 0.20 in a bilateral contrast between study group and control group, 312 individual will be required (156 in each group) to detect differences equal or higher than 15% between both groups in primary target. It has been estimated a tracking loss rates of 10%. It will be assumed as losts those individual impossible to be located, or those who do not accept to take part or those who do not attend to scheduled revisions, in accordance to the study intervention plan, as well as deceases occurring within six months since the intervention. Given the relevant impact of the development of cardioembolic or hemorrhagic events due to inappropriate INR control, changes about 15% could have great clinical relevance.
Variables. Operative definition The main variable to assess in this study is time on INR therapeutic levels in the last six months receiving VKA treatment. Appropriate INR level control will be assessed in two ways: measuring the therapeutic INR values percentages or Time percentages in therapeutic values estimated using Rosendaal method. It supposes to record the figure of INR value and the date in which the test was carried out. The therapeutic INR values percentages are defined by their acceptable values according to the pathology the patient suffers. It used to be from 2 to 3 if it is about atrial fibrillation or from 2.5 to 3.5 if thromboembolism prevention is carried out after a heart valve surgery has been performed. So, this quantitative variable has to be measured to calculate patients percentage on appropriate range, according to the patient condition.
Independent variables also called study variables are those which could affect to result variable. The investigators are going to classify them in eight groups to make easier their analysis.
Sociodemographic: age and gender. Somatometry and vital signs: Body mass index (BMI), diastolic and systolic blood pressure, and heart rate.
Cardiovascular risk factors: smoking habit, diabetes, arterial hypertension, dyslipidemia and chronic renal failure.
Cardiovascular conditions: atrial fibrillation (AF), interventional cardiac valve diseases with or without AF, ischemic cardiopathy, thromboembolic diseases history (stroke, transient ischemic attack), hemorrhagic stroke, congestive heart failure.
Blood test: Glomerular filtration rates, total cholesterol, HDL and LDL cholesterol and triglycerides. They will be obtained from the last blood test carried out to the patient.
Use of accompanying medication: total number of drugs, anticoagulant type. Consumption of "gastric protector".
Dietary habits: usual consumption of food rich in vitamin K, alcohol consumption.
Data collecting: All variables detailed previously were collected as long as they were suitable in digital medical history or it could be directly obtained from the patient during the medical interview, without the need of changing health center usual clinical practice, over the 6 months prior to the intervention.
First step: patients on OAT program enrolled in several primary health centers belonging to a healthcare area of Málaga were evaluated at the study moment attending to their clinical characteristics. The measurements obtained from the digital clinical history in the last six months before the beginning of the study were recorded, as well as the rest of variables.
Second step: Once the study of the VKA anticoagulation control degree has been performed, patients on inappropriate control were selected. A list of patients with deficient INR control in participant health centers was made. It was considered an inappropriate INR control when the therapeutic INR values percentages was less than 65%, using Rosendaal method to obtain them. In case of no availability, INR control was considered inappropriate when therapeutic INR values percentage resulted less than 60%. In any of the assumptions, the assessment period was at least the last six months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patient Education Group | Experimental | Behavioral: Patient education groupA group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls |
| Control group | No intervention | –Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients on VKA treatment for at least the last six months in primary care environment.
- Patients on inappropriate INR level control.
- Patients in whom we have access to, at least, 80% of their INR levels. controls in last six months of treatment with VKA, although they are enrolled in another primary care center.
- Patients who have given written informed consent to take part in the study
Key exclusion criteria (2 listed)
- Patients suffering from cognitive impairment wich prevents understanding what was written in the information sheet and informed consent.
- Limited mobility patients, terminal patients, alcoholism or drug addiction, severe psychiatric illness or any other reason which makes patients to be present at center´s meetings imposible.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient education groupAlso: Control groupGroup meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting | Behavioural | Patient Education Group |
Primary outcome
Time on INR therapeutic levels in the last six months receiving VKA treatment
Time frame: Six months
Appropriate INR level control will be assessed in two ways: measuring the therapeutic INR values percentages or Time percentages in therapeutic values estimated using Rosendaal method
25 secondary outcomes
Sociodemographic
Time frame: Six months
Body mass index (BMI)
Time frame: 0 and 12 months.
Diastolic and systolic blood pressure
Time frame: 0 and 12 months.
Heart rate
Time frame: 0 and 12 months.
Smoking habit
Time frame: 0 and 12 months.
diabetes
Time frame: 0 and 12 months.
Arterial hypertension
Time frame: 0 and 12 months.
Dyslipidemia
Time frame: 0 and 12 months.
Chronic renal failure
Time frame: 0 and 12 months.
Atrial fibrillation
Time frame: 0 and 12 months.
Interventional cardiac valve diseases with or without atrial fibrillation
Time frame: 0 and 12 months.
Ischemic cardiopathy
Time frame: 0 and 12 months.
Thromboembolic diseases history (stroke, transient ischemic attack)
Time frame: 0 and 12 months.
Hemorrhagic stroke
Time frame: 0 and 12 months.
Congestive heart failure
Time frame: 0 and 12 months.
Glomerular filtration rates
Time frame: 0 and 12 months.
Total cholesterol
Time frame: 0 and 12 months.
HDL Cholesterol
Time frame: 0 and 12 months.
LDL cholesterol
Time frame: 0 and 12 months.
Triglycerides
Time frame: 0 and 12 months.
Total number of drugs
Time frame: 0 and 12 months.
Anticoagulant type
Time frame: 0 and 12 months.
Consumption of "gastric protector"
Time frame: 0 and 12 months.
Usual consumption of food rich in vitamin K
Time frame: 0 and 12 months.
Alcohol consumption
Time frame: 0 and 12 months.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Sep 2018.
- Background: PubMed 22315269Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292.
- Background: PubMed 16517250Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006;117(5):493-9. doi: 10.1016/j.thromres.2004.11.025. Epub 2004 Dec 25.
- Background: PubMed 17577005Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67. doi: 10.7326/0003-4819-146-12-200706190-00007.
- Background: PubMed 20031794Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008 Nov;1(2):84-91. doi: 10.1161/CIRCOUTCOMES.108.796185. Epub 2008 Nov 5.
- Background: PubMed 22555213Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. Epub 2012 May 3. No abstract available.
- Background: PubMed 21757483Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011 Oct;13(10):1375-85. doi: 10.1093/europace/eur194. Epub 2011 Jul 14.
- Background: PubMed 24774588Gomez-Doblas JJ, Muniz J, Martin JJ, Rodriguez-Roca G, Lobos JM, Awamleh P, Permanyer-Miralda G, Chorro FJ, Anguita M, Roig E; OFRECE study collaborators. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol (Engl Ed). 2014 Apr;67(4):259-69. doi: 10.1016/j.rec.2013.07.014. Epub 2013 Nov 25.
- Background: PubMed 19932788Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009 Dec 1;104(11):1534-9. doi: 10.1016/j.amjcard.2009.07.022.
- Background: PubMed 19503778Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165-77. doi: 10.2147/cia.s4308. Epub 2009 May 14.
- Background: PubMed 19762550Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.
- Background: PubMed 21282258Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124.
- Background: PubMed 20802247European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. No abstract available.
- Registered follow-up of individualized pharmacological treatment in patients with oral anticoagulationLink provided by the sponsor.
Related trials for Health Education
Not yet recruitingObservational study
Validation of the Healthcare Relationship Assessment Scale (ERA) in Health Sciences Students.
Health Adult Subjects, Communication
Not yet recruiting
Mobile Game-Based Versus Classic First Aid Education in Adolescents: Randomized Controlled Trial
First Aid, Health Education in Schoolchildren
Recruiting
Estimating the Impact of Sexuality Education and Mobile Health Services on Reproductive Health and Empowerment Among Adolescents in Sierra Leone for the Family Planning Impact Lab
Reproductive Health, Sexual Health
Not yet recruiting
The Effectiveness of Comic-based Learning Materials on Nursing Students' Knowledge, Attitudes, and Confidence in Dementia Care
Dementia Care Education, Students, Nursing
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francisco J Navarro Moya, Enfermera contact
Francisco J Navarro Moya, Enfermera study chair
Servicio de salud pública de Andalucía. Málaga, España
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patient education group in people with Health Education and Patient Education as Topic, run by Francisco Javier Navarro Moya at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Francisco J Navarro Moya, Enfermera (34951031325 ext. 768238, fjavier.navarro.sspa@juntadeandalucia.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time on INR therapeutic levels in the last six months receiving VKA treatment (time frame: Six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03647254, which also lists 26 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2018.